Individualizing IgG4-RD Treatment Around Comorbidities and Limited Options

"Individualizing IgG4-RD Treatment Around Comorbidities and Limited Options" explores the gap between personalized treatment in principle and the choices available in practice.

Dr. Culver asks Dr. Della Torre which factors guide individualized treatment, including comorbidities and the route of administration. He says he would like to weigh organ involvement, comorbidities, and patient preference for the route of administration. In practice, however, the factors that weigh most heavily lie outside the patient and the physician. Clinicians cannot individualize among ten drugs. In most cases, they choose between just two strategies: glucocorticoids and B-cell depletion.

Dr. Della Torre adds that national regulations and uneven drug availability worldwide further constrain decisions. In regions where B-cell depletion has not been available, clinicians must rely on creativity to devise second- or third-line regimens. When he can weigh patient factors, he considers comorbidities first. The disease responds well to available therapies regardless of the organ involved. The decision therefore often hinges on the patient's other conditions rather than the site of disease.

Most patients are older and already have conditions such as cardiovascular disease, obesity, or osteoporosis. In these patients, Dr. Della Torre avoids glucocorticoids wherever possible. In his practice, he uses the lowest possible glucocorticoid dose and tailors treatment. His goal is to bridge patients to B-cell depletion as quickly as he can. He still uses conventional immunosuppressive drugs in a few cases, mainly driven by the patient's comorbidities.

Dr. Culver adds infection risk as another important consideration, especially in older patients and those with diabetes. Although clinicians cannot always choose the route of administration, she notes that patient preference varies. Some patients prefer oral therapy, some subcutaneous injections, and others intravenous infusions. Preference may depend on where they live, their ability to take the medication, and their comfort with each approach. Without a strict policy, she argues, flexibility is warranted to fit treatment to each patient's circumstances.

The next episode in this series, "Rethinking Glucocorticoids as First-Line Therapy in IgG4-RD," features Dr. Katz explaining why he has moved away from glucocorticoids as first-line therapy for most patients.